The influence of peri-menopausal estrogen replacement therapy upon protein synthesis in the liver was investigated. Changes in the cortisol-binding capacity of transcortin (TC-BC) were utilized as an indicator of hepatic estrogen sensitivity. Forty-two climacteric women were studied before and after treatment with various drugs at different doses (patients receiving identical compounds served as their own controls for the evaluation of dosage effects; duration of medication: 14 days at each dose). Oral administration of estriol (1 and 2 mg daily; n = 6), estriol (1 and 2 mg daily) + estradiol-17.beta. (2 and 4 mg daily; n = 8), estradiol valerate (1, 2, 4 and 6 mg daily; n = 6), conjugated equine estrogens (0.3 and 0.6 mg daily; n = 6), sodium estrone sulfate (0.8 and 1.6 mg daily) + sodium equilin sulfate (0.2 and 0.4 mg daily; n = 6) and quinestrol (25 .mu.g daily; n = 6) failed to alter TC-BC. However, ingestion of higher doses of conjugated equine estrogens (0.9 and 1.25 mg daily; n = 5) and quinestrol (50 .mu.g daily; n = 6) caused a significant rise (P < 0.01). Ethinylestradiol was given orally as a reference substance and elicited an elevation of expected magnitude. Vaginal administration of dienestrol cream (1 mg daily; n = 4) did not change TC-BC. The hepatotrophic effects of replacement estrogens evidently vary depending on the preparation and dosage selected for treatment.